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Background: The pathogenesis of COPD is complex and remains poorly understood. The European Respiratory
Society Study on Chronic Obstructive Pulmonary Disease (EUROSCOP) investigated long-term effects of budesonide;
18% of the COPD participants were atopic. So far effects of atopy on the long-term course of COPD have not been
elucidated.
Methods: Factors related to the presence of atopy (positive phadiatop) in 1277 mild-to-moderate COPD patients
participating in EUROSCOP were analysed using regression analysis. Incidence and remission of respiratory
symptoms during 3-year follow-up were analysed using generalised estimating equations models, and association
of atopy with lung function decline using linear mixed effects models.
Results: Independent predisposing factors associated with the presence of atopy were: male gender (OR: 2.21; 95%
CI: 1.47–3.34), overweight/obese (OR: 1.41; 95% CI: 1.04–1.92) and lower age (OR: 0.98; 95% CI: 0.96–0.99). Atopy was
associated with a higher prevalence of cough (OR: 1.71; 95% CI: 1.26–2.34) and phlegm (OR: 1.50; 95% CI: 1.10–2.03),
but not with lung function levels or FEV1 decline. Atopic COPD patients not treated with budesonide had an
increased incidence of cough over time (OR: 1.79, 95% CI: 1.03–3.08, p = 0.038), while those treated with
budesonide had increased remission of cough (OR: 1.93, 95% CI: 1.11–3.37, p = 0.02) compared to non-atopic COPD
patients.
Conclusions: Atopic COPD patients are more likely male, have overweight/obesity and are younger as compared
with non-atopic COPD patients. Atopy in COPD is associated with an increased incidence and prevalence of
respiratory symptoms. If atopic COPD patients are treated with budesonide, they more often show remission of
symptoms compared to non-atopic COPD patients who are treated with budesonide. We recommend including
atopy in the diagnostic work-up and management of COPD.
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Atopy, coming from the Greek atopos, meaning “out of
place”, refers to the hereditary predisposition to produce
Immunoglobulin E (IgE) antibodies against common en-
vironmental allergens. This may lead to clinical expression
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reproduction in any medium, provided the oratopic eczema [1]. The prevalence of atopic disorders has
increased over recent decades [2] and a decrease in micro-
bial exposure and changes in lifestyles (e.g. dietary habits,
obesity, less physical activity) have been suggested to be
causative factors [3].
In asthma, most patients have an atopic phenotype [1],
a feature that is associated with less severe disease and
better lung function [4]. Furthermore, it is well known
that atopic asthmatics respond better to corticosteroids
as they have an eosinophilic inflammatory pattern in the
airway wall compared to non-atopic asthmatics [5,6].
Therefore, recommendations for the treatment of allergyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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In contrast, in chronic obstructive pulmonary disease
(COPD), a common and disabling smoking-related disease
responsible for considerable morbidity and mortality
worldwide [7], the international diagnostic and treatment
guidelines do not incorporate recommendation for the
treatment of allergy. This lack of recommendations is
largely due to insufficient knowledge on the role of atopy
in the pathogenesis and outcome of COPD. Nevertheless,
it has been reported that around 18% of COPD patients
are atopic [8,9] and that atopy is a possible risk factor for
developing COPD [10-13]. Therefore, there has been a
growing interest in finding the link between atopy and
COPD and its consequence on the disease outcome. How-
ever, the effect of atopy on respiratory symptoms or lung
function in COPD patients has not been studied yet.
Understanding this issue is of clinical importance as it
may help to know the prognosis and to apply appropriate
medical interventions for atopic and non-atopic COPD
patients.
The European Respiratory Society Study on Chronic
Obstructive Pulmonary Disease (EUROSCOP) has mea-
sured the atopic status in its study population. EURO-
SCOP is a large multi-centre study performed in 39
centers in 9 European countries and has been designed to
assess the effect of 3-year treatment with inhaled budeso-
nide on lung function decline in smoking COPD patients.
The results showed a small improvement in lung function
after 6 months in the treated group but no differences in
long-term lung function decline [8]. So far, the effect of
atopy on lung function and respiratory symptoms was not
evaluated in this large longitudinal study. Therefore, we
assessed factors associated with the presence of atopy in
this COPD population and investigated whether there is a
difference between atopic and non-atopic COPD patients
regarding prevalence, incidence and remission of respira-
tory symptoms as well as lung function decline over the 3-
year follow-up of the study.
Methods
Subjects
We analysed data from the EUROSCOP study [8,9,14],
included 1277 COPD patients (from nine European
countries) aged 30–65 years who had failed to quit
smoking during a 3-month smoking-cessation program.
They were currently smoking ≥ 5 cigarettes/day, had
smoked for ≥10 years or had a smoking history of ≥5
packyears. Post-bronchodilator FEV1 was between 50
and 100% of the predicted value, and the ratio of pre-
bronchodilator FEV1 to slow vital capacity (VC) was
<70%. Subjects with a history of asthma, reversible air-
flow limitation, any atopic diseases like allergic rhinitis,
or allergic eczema and those who had used oral gluco-
corticoids for ≥4 weeks during the prior six months wereexcluded. The participants were allocated to two treat-
ment groups in a randomised, double-blind parallel-con-
trolled way, either receiving twice daily 400 μg budesonide
(Pulmicort, Astra, Stockholm, Sweden) or placebo from a
dry-powder inhaler (Turbuhaler, Astra) for a period of
3 years. Approval from regulatory and ethics committees
was obtained at all centers. All subjects gave written
informed consent.
Measurements
At baseline height, weight, and smoking habits were
assessed. BMI (weight/height2) was divided into 3 cat-
egories: underweight (<18.5 kg/m2), normal weight
(18.5–24.9 kg/m2), and overweight/obesity (≥25 kg/m2)
[15]. Atopy was determined in 1163 patients by measur-
ing specific IgE, using the Phadiatop test (Pharmacia &
Upjohn, Uppsala, Sweden). Total serum IgE level was
measured in 678 patients [8]. Information on respiratory
symptoms was assessed at baseline and annually there-
after [8]. The symptoms analysed in the present study
were: 1) cough in the morning, during the day or at
night in winter, 2) phlegm in the morning, during the
day or at night in winter, 3) wheezing/whistling in the
chest at any time, 4) attacks of shortness of breath after
activity, 5) ever trouble with breathing and 6) woken
with a feeling of tightness in the chest [9].
Spirometry, using the criteria of the American Thor-
acic Society [16], was performed at baseline and at 3-
monthly intervals using a dry rolling-seal spirometer.
Post-bronchodilator FEV1 was obtained 15 min after in-
halation of 1 mg terbutaline [8]. Reference values of the
European Respiratory Society [17] were used to calculate
FEV1% predicted.
Statistical analyses
1) Possible predictors for the presence of atopy (positive
Phadiatop) were analyzed using univariate analyses at
baseline. Given the fact that the prevalence of atopy dif-
fers between males and females [18-20], we stratified for
gender. Differences between atopics and non-atopics
were assessed in the gender strata using 2-sample Stu-
dent’s t test or rank-sum test (where appropriate) for
continuous variables (age and packyears) and χ2 test or
Fisher’s exact test for categorical variables (sex and
BMI). Subsequently a multivariate (unstratified) model
adjusted for gender was performed using logistic regres-
sion, including all variables with a p value <0.30 in either
the male or female univariate analysis. As the number of
subjects with underweight was very low (Table 1), we
combined underweight with normal weight in the multi-
variate regression analyses.
2) Differences in the prevalence of respiratory symp-
toms at baseline between atopics and non-atopics were
analyzed using χ2 test. Multiple logistic regression
Table 1 Characteristics of atopic and non-atopic COPD patients in the EUROSCOP study stratified by gender
Baseline variables Males (843 patients) Females (320 patients)
Atopic Non-atopic p. value Atopic Non-atopic p. value
n = 181 n = 662 n = 32 n = 288
Age, yr 53.0 (48.0–58.0) 54.0 (48.0–59.0) 0.164 51.0 (46.0–58.7) 52.0 (47.0–58.0) 0.391
Height, cm 176 (172–181) 176 (171–180) 0.403 165.5 (160.5–169.7) 165 (160–169) 0.494
Weight, kg 80.0 (72.0–88.0) 78.0 (70.0–85.0) 0.017 64.0 (58.5–73.7) 62.0 (55.0–70.0) 0.206
BMI, kg/m2 25.3 (23.5–27.5) 24.8 (22.6–27.1) 0.016 23.8 (21.8–25.9) 22.9 (21.0–25.4) 0.205
Underweight (<18.5) 2 (1.1%) 7 (1.1%) 0 (0.0%) 17 (5.9%)
Normal weight (18.5–24.9) 77 (42.5%) 342 (51.7%) 0.102# 20 (62.5%) 186 (64.6%) 0.277#
Overweight/Obese (≥25) 101 (55.8%) 312 (47.1%) 12 (37.5%) 84 (29.2%)
Packyears of smoking 40.0 (29.2–55.5) 38.7 (28.5–50.0) 0.288 32.5 (26.7–36.0) 29.9 (21.3–39.0) 0.462
FEV1, liter
* 2.7 (2.4–3.3) 2.8 (2.3–3.2) 0.680 2.1 (1.6–2.4) 2.0 (1.7–2.4) 0.904
FEV1 % pred.
* 78.7 (69.4–87.0) 79.3 (68.1–89.1) 0.685 79.4 (63.6–89.2) 80.8 (70.5–88.5) 0.666
FEV1%FVC
* 63.9 (56.7–68.5) 64.4 (58.1–68.7) 0.443 66.4 (61.4–70.0) 65.5 (60.9–70.4) 0.823
Reversibility % pred. 2.9 (0.8–5.2) 2.8 (0.0–5.4) 0.932 3.2 (0.3–7.6) 2.9 (0.0–5.5) 0.323
Total IgE, kU/l** 248.5 (84.0–617.2) 37.0 (15.0–82.0) <0.0001 161.0 (25.5–1373.0) 28.0 (13.0–75.0) 0.002
Data are presented as median (interquartile range) or number (%). Bold p-values lower than 0.05 indicate significant differences between atopic and non-atopic
patients within males or females.
*Respiratory function tests were performed after inhalation of 1 mg terbutaline.
**Available in 678 patients.
#P.value refers to Chi-square analysis between classes of BMI and atopy.
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for each symptom separately to investigate the associ-
ation between atopy and respiratory symptoms at base-
line. This analysis was performed for the total population,
stratified for gender, and interactions between atopy and
gender were investigated.
3) Association between atopy and changes in the pres-
ence of respiratory symptoms during the study period
were analysed using generalised estimating equation
(GEE) models as described by Watson et al. [9]. In brief,
pairs of observations were formed between the baseline
and the first 12-monthly visit (0–12 months), and be-
tween 12–24 months and 24–36 months. In the analysis
on symptom incidence, only paired observations where
the symptom under study was not present at the first
observation of the pair were included. The symptom sta-
tus at the second observation of the pair was taken as
the outcome variable. For the analyses on symptom re-
mission only paired observations where the symptom
under study was present at the first observation of the
pair were included. Each person could contribute one to
three paired observations. For the incidence and remis-
sion of each symptom, Odds ratios (ORs) for atopy were
calculated. These analyses were performed for the two
treatment groups separately as ICS treatment may mod-
ify the association between atopy and symptom inci-
dence/remission. In addition, this effect modification by
treatment was investigated by entering an interaction
term between atopy and treatment in the unstratified
models. The analyses were further stratified by genderand were adjusted for age, BMI, atopy, packyears, and
FEV1 % predicted, all measured at baseline.
4) To investigate the association between atopy and
FEV1 decline over time, linear mixed effects models were
used. Since the FEV1 decline in EUROSCOP is not linear
over time, two separate periods (0–6 and 6–36 months)
were investigated [8]. The models were stratified for




The baseline characteristics of the atopic and non-
atopic males and females are shown in Table 1. In total,
213 (18.3%) patients were atopic. Atopy was more
prevalent in males than females [21.5% and 10% re-
spectively, p < 0.001]. Atopic males had a higher weight
(p = 0.017) and BMI (p = 0.016) than non-atopic males.
Atopic patients had significantly higher total serum IgE
(kU/l) levels than non-atopic patients (p < 0.0001 in
males and p = 0.002 in females). There were no signifi-
cant differences in age and lung function parameters at
baseline between atopic and non-atopic patients.
Factors associated with the presence of atopy
Multiple logistic regression analysis showed that male gen-
der (OR: 2.21; 95% CI: 1.47–3.34), overweight/obese (OR:
1.41; 95% CI: 1.04–1.92) and lower age (OR: 0.98; 95% CI:
0.96–0.99) were independently associated with the pres-
ence of atopy. There was no significant association
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0.99–1.01) and the presence of atopy.
Atopy and respiratory symptoms
Atopic patients had a higher prevalence of cough (p = 0.02)
and phlegm (p = 0.08) than non-atopic patients (Table 2).
After stratifying by gender, a higher prevalence of cough
(p < 0.0001) and phlegm (p = 0.008) was found in atopic
males than non-atopic males, without a significant differ-
ence in females (Table 2). Woken with chest tightness was
more prevalent in atopic females than non-atopic females
(p = 0.042) (Table 2). In the multiple logistic regression
model adjusted for confounders, atopy was associated with
a higher prevalence of cough (OR: 1.71; 95% CI: 1.26–2.34)
and phlegm production (OR: 1.50; 95% CI: 1.10–2.03) in
the total population, and with woken with chest tightness
in females only (OR females: 2.69; 95% CI: 1.11–6.55, OR
male: 0.84; 95% CI: 0.47–1.49, female vs male: OR: 3.21;
95% CI: 1.12–9.25).
Atopy and incidence and remission of symptoms
The association between atopy and incidence and remis-
sion of symptoms during the 3 years of the study, strati-
fied by treatment group and gender is shown in Tables 3
and 4 respectively.
In the placebo group, atopy was significantly associated
with an increased incidence of cough (OR: 1.79, 95% CI:
1.03–3.08, p = 0.038). Atopy was not significantly associated
with the incidence of the other symptoms.
Analyses on remission of symptoms showed that
remission of cough was higher in atopic than non-atopic
patients receiving budesonide (OR: 1.93, 95% CI: 1.11–3.37,
p = 0.02). After stratifying by gender, remission of cough
was higher in atopic males than non-atopic males receiving
budesonide (OR: 1.94, 95% CI: 1.05–3.57, p = 0.034) as was
trouble with breathing (OR: 2.76, 95% CI: 1.45–5.26,
p = 0.002), but differences were not present in female sub-
jects receiving budesonide. In contrast, atopic females re-
ceiving placebo, had increased remission of woken withTable 2 Respiratory symptoms in atopic and non-atopic COPD
Respiratory symptoms Total population
1163 patients
Atopic Non-atopic
n (%) n (%)
Subjects number 213 (18.3) 950 (81.7)
Wheezing at anytime 111 (52.1) 527 (55.5)
Cough day/night or a.m. 155 (72.8)* 609 (64.1)
Phlegm day/night or a.m. 127 (59.6)# 498 (52.4)
Trouble with breathing 104 (48.8) 443 (46.7)
Woken with chest tightness 24 (11.3) 102 (10.7)
Attack of dyspnea after activity 82 (38.5) 350 (36.8)
*Significant difference between atopic and non-atopic patients at p < 0.05. #: p = 0.0chest tightness (OR: 5.76, 95% CI: 1.67–19.86, p = 0.006)
than non-atopic females receiving budesonide.
The incidence and remission of cough and phlegm
production in two treatment groups are shown in
Figure 1.
Atopy and lung function decline
There was no significant difference in changes of post-
bronchodilator FEV1 between atopic and non-atopic
patients neither in males nor in females, a finding that
was true for both placebo and budesonide treated groups
during month 0 to 6 (Figure 2). From 6 to 36 months,
atopic females who received placebo showed a smaller
decline in FEV1 compared to the non-atopic females in
the placebo group (p = 0.008, Figure 2).
Discussion
Our study shows that male gender, overweight/obesity
and lower age are independently associated with the
presence of atopy in COPD. Moreover, atopic patients
showed a higher prevalence of respiratory symptoms
than non-atopics. Interestingly, atopic patients without
ICS treatment more frequently developed respiratory
symptoms than non-atopics, while atopic patients on
treatment with ICS showed increased remission of re-
spiratory symptoms compared to non-atopic patients.
We found that the prevalence of atopy is two times
higher in males than females both in univariate and
multivariate analyses. This confirms previous findings in
the literature. Sears et al. found that boys (age of
13 years) had a higher prevalence of positive skin tests
and a higher response to house dust mite and cat than
girls with the same age [21]. With increasing age, a sig-
nificant decrease in male/female ratio of sensitization
was described after the age of 8 years although a male
predominance persists [18] also in older men [19,20].
This can be explained by a population study in adults
which showed that atopy significantly decreased after
menopause in both asthmatic and non asthmaticpatients at baseline stratified by gender
Males Females
843 patients 320 cases
Atopic Non-atopic Atopic Non-atopic
n (%) n (%) n (%) n (%)
181 (21.5) 662 (78.5) 32 (10) 288 (90)
95 (52.5) 353 (53.3) 16 (50) 174 (60.4)
110 (60.8)* 291 (44.0) 18 (56.2) 170 (59.0)
87 (48.1)* 244 (36.9) 12 (37.5) 101 (35.1)
85 (47.0) 287 (43.4) 19 (59.4) 156 (54.2)
16 (8.8) 68 (10.3) 8 (25.0)* 34 (11.8)
68 (48.1) 234 (35.3) 14 (43.8) 116 (40.3)
8.
Table 3 Association between atopy and incidence of respiratory symptoms stratified by the treatment group and
gender
Respiratory symptom Total population Males Females
OR (95% CI) of atopy OR (95% CI) of atopy OR (95% CI) of atopy
Placebo Budesonide Placebo Budesonide Placebo Budesonide
Wheezing at any time 1.15 (0.71–1.87) 0.79 (0.45–1.43) 1.24 (0.74–2.08) 0.92 (0.48–1.75) 0.64 (0.15–2.78) 0.43 (0.10–1.85)
Cough day/night or a.m. 1.79 (1.03–3.08)* 0.83 (0.42–1.62) 1.69 (0.93–3.08)# 0.84 (0.38–1.84) 2.52 (0.64–9.86) 0.60 (0.17–2.08)
Phlegm day/night or a.m. 1.50 (0.84–2.69) 0.91 (0.54–1.53) 1.55 (0.82–2.93) 0.85 (0.46–1.59) 1.30 (0.36–4.67) 0.92 (0.38–2.27)
Trouble with breathing 1.12 (0.66–1.89) 0.68 (0.37–1.24) 1.09 (0.59–1.99) 0.79 (0.42–1.51) 1.23 (0.44–3.44) 0.22 (0.4–1.13)#
Woken with chest tightness 1.33 (0.74–2.38) 1.07 (0.57–1.99) 1.35 (0.69–2.65) 1.08 (0.55–2.12) 1.08 (0.27–4.34) 1.11 (0.23–5.39)
Attack of dyspnea after activity 0.98 (0.59–1.62) 1.49 (0.88–2.51) 0.76 (0.43–1.33) 1.55 (0.88–2.73)$ 2.79 (0.94–8.31)# 0.89 (0.22–3.62)
*OR is significant at p < 0.05. Each model was adjusted for sex, age, BMI, pack years of smoking, number of cigarettes and FEV1 % pred.
#Trend (0.05 < p. value < 0.1).
$Interaction between Phadiatop and treatment group has a p.value < 0.05.
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changes over the lifespan depends on the hormonal pat-
tern [19]. We corroborate these findings by showing a
male preponderance of atopy in COPD.
Younger age was also associated with the presence of
atopy in our COPD patients. This finding is in line with
results from studies in the general population showing
that allergen sensitivity and the incidence of atopic dis-
orders decreases with age [22-25].
Another interesting finding in our study was that over-
weight/obesity was associated with the presence of atopy
in COPD patients. The previous studies in the general
population also showed a significant association between
overweight/obesity and atopy in adolescents [26] and in
adults [24]. In asthma, it has been suggested that the
systemic inflammatory effects of obesity itself may en-
hance eosinophilic airway inflammation [27]. We do not
know whether this is also true for COPD and the atopy-
overweight/obesity relationship in COPD has to be fur-
ther explored.
With respect to respiratory symptoms, our study
revealed a higher prevalence of cough and phlegm in
atopic COPD patients compared to non-atopic COPD
patients indicating that atopy (i.e. positive phadiatop)
contributes importantly to symptoms in COPD. TheTable 4 Association between atopy and remission of respirat
gender
Respiratory symptom Total population Mal
OR (95% CI) of phadiatop OR
Placebo Budesonide Plac
Wheezing at any time 0.99 (0.59–1.67) 1.18 (0.70–1.99) 0.88
Cough day/night or in a.m. 0.85 (0.53–1.36) 1.93 (1.11–3.37)*,$ 0.87
Phlegm in day/night or in a.m. 1.21 (0.72–2.03) 1.67 (0.99–2.82)# 1.14
Trouble with breathing 0.84 (0.48–1.47) 1.76 (0.99–3.11)# 0.96
Woken with chest tightness 2.18 (0.97–4.90)# 2.32 (0.60–8.91) 2.17
Attack of dyspnea after activity 1.01 (0.52–1.95) 1.11 (0.63–1.96) 1.04
*OR is significant at p < 0.05. Each model was adjusted for sex, age, BMI, pack years
#Trend (0.05 < p. value < 0.1). $Interaction between Phadiatop and treatment groupassociation between atopy and a higher prevalence of re-
spiratory symptoms was also found in the general popu-
lation, as various respiratory symptoms have been
associated with positive skin test reactivity [10,28] and
eosinophilia [28,29]. But in COPD, according to our
knowledge, there is no published paper showing an asso-
ciation between atopy and respiratory outcomes. One re-
cent ATS abstract [30] is in line with our findings,
investigating 1424 COPD patients from “The National
Health and Nutrition Examination Survey (NHANES)”
III (1988–1994). The investigators defined allergic/atopic
COPD subjects (n = 346) as the presence of any one of
the following criteria: at least one positive skin prick test,
self-reported doctor diagnosed hay fever, or symptoms
induced by house dust, animals or pollen. They found
that individuals with indications of allergic disease more
likely reported having episodes of sinusitis, and an add-
itional trend towards more frequent reporting of cough
and wheeze [30] compared to non-allergic individuals.
Our study defined atopy objectively by specific IgE posi-
tivity and excluded subjects with a history of asthma, al-
lergic rhinitis, or allergic eczema. As we excluded
subjects with allergic diseases, we believe our data more
closely reflects the effect of atopy on COPD-related
cough. Regarding the importance of cough and phlegm,ory symptoms classified by the treatment group and
es Females
(95% CI) of phadiatop OR (95% CI) of phadiatop
ebo Budesonide Placebo Budesonide
(0.48–1.60) 1.26 (0.70–2.26) 2.06 (0.55–7.78) 0.51 (0.15–1.71)
(0.52–1.45) 1.94 (1.05–3.57)* 0.79 (0.26–2.41) 1.84 (0.47–7.30)
(0.65–2.00) 1.63 (0.93–2.87)# 1.48 (0.34–6.45) 1.53 (0.28–8.26)
(0.50–1.82) 2.76 (1.45–5.26)*,$ 0.47 (0.18–1.21) 0.43 (0.17–1.12)#
(0.67–6.99) 1.33 (0.22–7.85) 5.76 (1.67–19.86)* 8.82 (0.63–123.66)
(0.49–2.20) 0.87 (0.46–1.64) 1.03 (0.29–3.63) 3.67 (0.68–19.70)
of smoking, number of cigarette and FEV1 % pred.



























































Figure 1 Effect of atopy on incidence and remission of cough
and phlegm in the treatment groups. Logistic regression with
adjustment for age, BMI, packyears, and FEV1 % predicted.






























































































Figure 2 Monthly change of FEV1 from 6 months to 36 months
after the start of the study medication. Linear mixed effect
models with adjustment for age, BMI, atopy, packyears, and FEV1
% predicted.
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lent in COPD patients and have been reported to predict
disease progression, exacerbations and hospitalizations
[31]. It has been argued that these symptoms can consti-
tute a sign of inflammation and may identify patients at
higher risk of clinical worsening [31]. Thus, our finding
that atopy associates with this clinical phenotype may
have important consequences for future studies on inter-
vention in this phenotype with an important clinical im-
pact on COPD, as shown in our study.
Our study did not show a significant difference in lung
function parameters between atopic and non-atopic
patients, with the exception of FEV1 decline. Of interest,
atopic female COPD patients not using ICS treatment
demonstrated a slower decline in lung function than non-
atopic females. Additionally, if atopic females used ICS
this protective effect of atopy was no longer present. In
established COPD, to our knowledge, such an effect of
atopy has never been investigated. We do not have a clear
explanation for the latter finding, but as this observation is
not present in male subjects, we speculate that hormonal-
related effects on the immune system play a role. How-
ever, the number of atopic females in our study was low
(n = 32); so firm conclusions cannot be drawn.
It has been shown that atopy is associated with a lower
level of lung function [32,33] and FEV1 decline [34] in the
general population and also FEV1 decline in healthy
former and current smokers [35]. We conclude that, un-
like in healthy subjects, atopy is not associated with accel-
erated decline in lung function in established COPD. Itmay well be that the effects of atopy are overshadowed by
the effects of smoking in our COPD population.
Our study showed that in atopic COPD patients the
use of budesonide is associated with higher remission
rates of cough and phlegm, whereas placebo is asso-
ciated with higher incidence rates. This is an important
finding as cough and phlegm predict disease progres-
sion, exacerbations and hospitalizations [31]. Although
this beneficial effect of budesonide may not be specific
for atopic COPD and may be present in every atopic
subject, the question rises whether we should treat all
atopic COPD patients with an ICS (as EUROSCOP
included only steroid-naïve patients). Indeed, already in
1978, Sahn suggested that atopic COPD patients are the
ones who benefit most from corticosteroid treatment
[36]. If we accept that atopic COPD patients from now
on should be treated with ICS, this would widen the
present indications for ICS as defined by GOLD (Global
Initiative for Chronic Obstructive Lung Disease) [37]. At
this moment GOLD recommends ICS use for symptom-
atic patients with an FEV1 < 50% predicted (stage III, se-
vere COPD, and stage IV, very severe COPD) and
repeated exacerbations [37,38]. However, before consid-
ering to add atopic status as a guideline for ICS treat-
ment in COPD, more studies are needed confirming that
atopy is a risk factor for worse COPD outcome.
Conclusion
We conclude that atopy is present in COPD patients
and that the prevalence of atopy is higher in males, sub-
jects with overweight/obesity and younger patients. Im-
portantly, atopy in COPD is associated with a higher
prevalence and incidence of respiratory symptoms, while
Fattahi et al. Respiratory Research 2013, 14:10 Page 7 of 8
http://respiratory-research.com/content/14/1/10when being treated with ICS, the patients have higher
remission rates. However, atopy in COPD is not asso-
ciated with accelerated but rather decelerated FEV1 de-
cline in females. Our results clearly indicate that the
atopic status should not be forgotten in the routine
work-up of COPD. However, whether every atopic
COPD patient should be treated with an ICS needs to be
confirmed in future studies.
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